Efficacy And SafetyELVN-001 has shown a clean safety profile with low rates of adverse effects, dose reductions, and discontinuations.
Financial PositionEnliven strengthened their financial position by raising significant funds, ensuring financial stability through pivotal data milestones.
Market OpportunityThere is a significant market opportunity for ELVN-001, with a large patient population in the 2L+ and 3L+ CML settings.